-
1 Comment
Endo International plc is currently in a long term downtrend where the price is trading 41.1% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.6.
Endo International plc's total revenue sank by 0.6% to $760M since the same quarter in the previous year.
Its net income has increased by 154.6% to $119M since the same quarter in the previous year.
Finally, its free cash flow fell by 1400.9% to $-559M since the same quarter in the previous year.
Based on the above factors, Endo International plc gets an overall score of 2/5.
Sector | Healthcare |
---|---|
Industry | Pharmaceuticals |
Exchange | NASDAQ |
CurrencyCode | USD |
ISIN | USG304011061 |
PE Ratio | None |
---|---|
Market Cap | 69M |
Target Price | 1 |
Dividend Yield | 0.0% |
Beta | 1.15 |
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ENDP using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025